Frazier Life Sciences and Lightspeed Venture Partners led a $150m Series C round in Scorpion Therapeutics.

Venture capital firms Frazier Life Sciences and Lightspeed Venture Partners led a $150m Series C round in Scorpion Therapeutics, a pioneering clinical-stage oncology company, with participation from Omega Funds, Vida Ventures, Atlas Venture, Abingworth, Fidelity Management & Research Company, Boxer Capital, EcoR1 Capital, LLC, Surveyor Capital (a Citadel company), Invus, Wellington Management, Nextech Invest, OrbiMed, Logos Capital, Woodline Partners, and Casdin Capital. "The robust demand for this capital raise is a testament to Scorpion's continued clinical execution, the strength of our emerging clinical data, and the quality of our rapidly advancing pipeline," Adam Friedman, Scorpion CEO.